A new Alzheimer’s drug, once worth billions, is headed for the trash
(By Damian Garde for STAT) Axovant Sciences (AXON), 2017’s most talked-about biotech company, is abandoning the drug that made it
Read More
Part D/Prescription Drugs
HHS Nominee Vows To Tackle High Drug Costs, Despite His Ties To Industry
(By Emmarie Hetteman for Kaiser Health News) Senate Democrats on Tuesday pressed President Donald Trump’s nominee for the top health
Read MoreAn Opioid Remedy That Works: Treat Pain And Addiction At The Same Time
(By John Daley, Colorado Public Radio in reporting partnership with NPR, Colorado Public Radio and Kaiser Health News) Seven years
Read MoreCloud Of Uncertainty Over Legalized Pot As Feds End Obama-Era Accommodation
(By Anna Groman and Phil Galewitz for California Healthline produced by Kaiser Health News) Three days after California businesses began
Read MoreFrom Retirement To The Front Lines Of Hepatitis C Treatment
(By Julio Ochoa, WUSF for Kaiser Health News) When a hepatitis C treatment called Harvoni was released in 2014, Dr.
Read MoreDrugmakers’ annual price hikes lower in 2018 than previous years: 3 things to know
(By Mackenize Bean for Becker’s Hospital Review) After a year filled with immense scrutiny over high drug prices, drug companies
Read MoreDrug Overdose Deaths Plateau In California, Soar Nationally
(By Pauline Bartolone for California Healthline produced by Kaiser Health News) Even as the opioid crisis fueled overdose deaths across
Read MoreHospitals face $1.6B in Medicare payment cuts after judge dismisses lawsuit: 6 things to know
(By Ayla Ellison for Becker’s Hospital Review) A federal judge has dismissed an injunction requested by hospital groups and health
Read MorePharmacists Slow To Dispense Lifesaving Overdose Drug
(By Anna Gorman for Kaiser Health News) Gale Dunham, a pharmacist in Calistoga, Calif., knows the devastation the opioid epidemic
Read MoreRoche buys precision medicine firm Ignyta for $1.7B
(By Anuja Vaidya for Becker’s Hospital Review) Roche, a global pharmaceuticals and diagnostics company, is acquiring Ignyta for $27 per share in
Read More